Articles tagged with Statins
Researchers found that statin drugs can reverse learning deficits in mice with Neurofibromatosis type 1 (NF1), a condition affecting five percent of the world population. The treatment enables normal brain cell communication, creating physical changes in the brain and improving memory.
Researchers discovered that Lovastatin can reverse learning and attention deficits in adult Nf1 mutant mice, suggesting a potential treatment for the disorder. The findings also show that cognitive deficits associated with NF1 are not irreversible developmental deficits.
Researchers analyzed data from 79,994 women to evaluate associations of statins, lipid-lowering drugs, and serum cholesterol levels with breast cancer. No link was found between these factors and breast cancer risk.
Researchers analyzed data from a large trial and found no safety concerns for patients with very low LDL levels. The study suggests that intensive statin therapy may be beneficial even when LDL levels drop below targeted levels.
A significant association was observed between statin use and reduced fracture risk in a large cohort of mostly male veterans. The study, published in the Journal of the American Medical Association (JAMA), found that statins reduced fracture risk by 36% compared to no lipid-lowering therapy.
A new study published in the American Journal of Cardiology found that early statin therapy can significantly reduce mortality and other complications in heart attack victims. Patients who received statins before or within 24 hours of hospitalization had a 54% lower risk of in-hospital mortality, compared to those not on statin therapy.
Patients taking statins prior to hospital admission with community-acquired pneumonia were 2.8 times less likely to die than those not on statins. Statins' impact on the immune system may contribute to their protective effect on patients suffering from pneumonia.
A large cohort study of over 2,798 participants aged 65 or older found no significant reduction in dementia risk among those who used statins. The authors suggest that statin exposure may need to occur earlier in adulthood or for longer periods to prevent dementia.
A new study demonstrated add-on effects of ACTOS on diabetic dyslipidemia, reducing triglycerides and increasing HDL cholesterol. Patients with type 2 diabetes who switched from Avandia to ACTOS showed significant improvements in lipid levels, regardless of age or gender.
A new mechanism controlling cholesterol and lipid metabolism has been discovered, with the Fbw7 protein identified as a potential target for treating high cholesterol. The findings also suggest a connection between this protein and cancer, with aspects of its link to diabetes currently under investigation.
Researchers found a significant gap in statin use among patients with high and moderate risk of heart disease. Statin therapy was underused in these groups, with fewer than half of patient visits associated with use, despite being recommended for them.
A study analyzing national surveys found that many patients at high risk of cardiovascular disease are not receiving statin treatment. The authors conclude that education is needed to improve physicians' adherence to evidence-based medicine guidelines for cardiovascular risk reduction.
Researchers analyzed AERS reports for rosuvastatin and compared them to other statins, finding a higher rate of muscle and kidney complications. The absolute risk of AERS appears low, with most side effects disappearing upon withdrawal of medication.
Researchers found statin chemoprevention to be a promising strategy for managing patients with chronic ulcerative colitis, preventing 90-96% of colon cancers. Compared to frequent colonoscopic surveillance, this approach may improve quality of life and reduce costs.
Researchers found that statin use was associated with significant reductions in the risk of both pancreatic and esophageal cancers. Statins were shown to reduce the risk of pancreatic cancer by 59% and esophageal cancer by 56%.
A new study finds that statin therapy can significantly reduce hospitalization costs and costs of major vascular events. The cost-effectiveness of treatment varies depending on individual risk levels, with lower-risk groups potentially benefiting from statins.
A head-to-head retrospective analysis of 18,000 elderly patients with AMI found that five commonly prescribed statins were equally effective for secondary prevention. The study highlights the need to consider costs when selecting statins.
Patients on statins before a stroke had a 1.6 times higher chance of favorable outcomes compared to those not taking statins. Statin use after a stroke was associated with a 2.6 times increased probability of recovery.
The current dyslipidemia guidelines have raised controversy due to concerns that they may lead to more people being screened and prescribed statin therapy. The debate centers around the data used in the guidelines and its implications for patient care.
Research suggests statins can cause asymptomatic elevation of aminotransferases, especially at higher doses, but rare reports of significant liver injury exist; monitoring liver values is recommended for patients on statins, particularly those with known liver conditions.
Women with acute coronary syndrome are being prescribed aspirin, beta-blockers, and statins as frequently as men, according to a recent study. However, significant disparities remain in the use of lipid-lowering medications, with women living significantly longer after their hospitalization.
Research suggests that statins can increase 'healthy' (non-amyloidogenic) cleavage of amyloid precursor protein (APP), potentially protecting against Alzheimer's disease. In a study, two different statins increased healthy cleavage of APP in mouse neuroblastoma cells.
Researchers found that statins may break down toxic amyloid-beta by inhibiting the Rho/ROCK pathway, which could lead to new anti-amyloid drug targets. The study suggests that statins may be a promising strategy in treating Alzheimer's disease.
A study of 502 patients with coronary artery disease found that statin therapy lowered both LDL cholesterol and C-reactive protein levels, leading to slower disease progression. The research suggests that inflammation plays a key role in cardiovascular disease and may be useful in patient management.
A study analyzing claims data from 11 managed care health plans found that the risk of rhabdomyolysis is relatively low with three frequently prescribed statins. The study suggests that patients taking statins and fibrates combined, such as those with diabetes mellitus, should be monitored for symptoms suggestive of rhabdomyolysis.
The ARIES trial shows CRESTOR 10mg reduced LDL-C by 37%, compared to 32% for atorvastatin, with higher response rates among African-American patients. CRESTOR also improved HDL-C levels and reduced non-HDL-C and total cholesterol.
A large study reveals that co-administration of Zetia and fenofibrate significantly lowers LDL cholesterol, non-HDL cholesterol, and apo B to a greater extent than fenofibrate alone in mixed hyperlipidemia patients. This improvement is also seen in HDL cholesterol levels.
Crestor demonstrates improved lipid profiles and lower LDL-C targets than atorvastatin, achieving higher patient success rates with fewer doses. Crestor also shows effectiveness in reducing apolipoprotein B levels and improving the Apo B:Apo A-I ratio.
Researchers found an enzymatic pathway called Rho/ROCK plays a key role in the metabolism of APP, which is associated with Alzheimer's. The discovery may lead to novel anti-amyloid drugs and more specific therapies for Alzheimer's patients.
Researchers found that taking Welchol, a bile acid sequestrant, with TriCor, a fibrate, resulted in no significant interaction. The study involved 30 healthy volunteers who received different treatment regimens involving the two drugs, showing that co-administration is safe and effective.
The trial found that early and aggressive statin use can reduce the long-term incidence of heart attacks, death from heart attack, stroke or readmission to the hospital for a cardiac event. However, benefits only became evident longer term, with no differences in endpoints during the first four months.
A new study suggests that early initiation of intensive statin treatment after a heart attack may lower the risk of future cardiovascular events. The research found that participants who received high-dose simvastatin had better outcomes than those on a placebo, despite an increased risk of muscle-related side effects.
A study published in The Journal of the American Medical Association found that treating patients with recent acute coronary syndromes with higher doses of statins soon after experiencing heart-attack symptoms leads to a reduction in subsequent death, congestive heart failure, and other cardiac events compared to delayed treatment with...
The landmark PROVE IT-TIMI 22 trial found that a long-term regimen of antibiotics designed to kill Chlamydia pneumoniae does not reduce the risk of heart attacks or cardiovascular disease. Researchers recommend focusing on proven therapies like high-dose statin therapy and ACE inhibitors instead.
A recent study found that immediate statin therapy in hospitalized heart attack patients significantly reduced the risk of death and additional heart attacks. The study, which involved 3,605 patients at 260 medical centers, confirms earlier findings that early statin treatment is beneficial for heart health.
A Nordic study found statins decrease mortality rate and incidence of cancer over 10-year follow-up. Statin therapy with simvastatin reduced cardiovascular and coronary mortality, with a 17% reduction in cardiovascular mortality.
A study found that atorvastatin reduced cardiovascular events, deaths, and strokes by a third in patients with type 2 diabetes without high LDL cholesterol. The results suggest statin therapy may be safe and effective for this patient group.
Research on statins as a treatment for Alzheimer's disease has yielded conflicting results, with some studies showing improved cognitive function and others finding no benefit. Large-scale clinical trials are needed to resolve the questions raised by these studies.
Rosuvastatin, marketed as Crestor, has been linked to a higher incidence of rhabdomyolysis and renal insufficiency compared to other statins. The drug's manufacturer, AstraZeneca, is estimated to be seeking $20 billion in annual sales, making it morally unjustifiable to keep the drug on the market.
A small but statistically significant improvement was found in arthritis symptoms among patients given atorvastatin compared to those on placebo. The study suggests that statins could be used to prevent cardiovascular disease in patients with rheumatoid arthritis.
A study published in Archives of Ophthalmology found that long-term use of statins and nonstatin cholesterol-lowering medications was associated with a reduced risk of open-angle glaucoma. The study included 667 men with new diagnoses of glaucoma between 1997 and 2001.
Nearly half of patients prescribed statins fail to fill their prescriptions often enough or stop taking the drug altogether due to high out-of-pocket costs. Co-pay levels above $20 increase the likelihood of non-adherence, with four times more patients stopping medication when co-pays exceed $20 compared to those under $10.
A new study suggests that men who take statins, common cholesterol-lowering drugs, have a significantly reduced risk of prostate cancer. Statin use was associated with a 58% lower risk of prostate cancer and a 55% lower risk of elevated PSA levels.
A landmark UK study sponsored by Diabetes UK, Department of Health, and Pfizer UK showed that 10mg atorvastatin reduced cardiovascular events by 37% in patients with diabetes without existing CVD. Stroke was substantially reduced by 48% in these patients.
A study of 19,537 patients found that those taking cholesterol-lowering drugs statins before admission had better hospital outcomes than non-statin users. Meanwhile, researchers discovered limited information on the effectiveness of bioterrorism surveillance systems in detecting illnesses and emerging infections.
The UK government has rejected proposals to sell simvastatin over-the-counter for the primary prevention of heart disease due to financial reasons. This decision may increase inequalities as many people cannot afford the medication, which is currently prescribed to around 1.8 million people in the UK.
A recent study found that statins reduced brain lesions in people with MS by 44% after six months of treatment. Researchers suggest that statins may be beneficial for patients as monotherapy or as an add-on to existing therapies, but more data is needed to confirm their efficacy.
The American College of Physicians recommends statin therapy for adults with type 2 diabetes, regardless of cholesterol levels, due to the high risk of cardiovascular disease. The guidelines also emphasize the importance of monitoring liver function and muscle enzymes only in patients with pre-existing conditions.
Researchers found that statin use was associated with a 50% reduced risk of developing wet AMD, while aspirin use was linked to a 40% lower risk. The study suggests that these medications may prevent irreversible vision loss in older adults.
A new study found that patients who took statins before having a stroke had better outcomes compared to those who did not. However, statin use was not shown to reduce the severity of strokes.
A recent five-year study found that simvastatin therapy significantly reduces the incidence of ischemic strokes by 30%, while having no adverse effect on hemorrhagic strokes. The study also shows a substantial reduction in combined major vascular events among patients with cerebrovascular disease.
The REVERSAL study found that intensive statin therapy resulted in greater reductions in LDL-cholesterol and C-reactive protein, as well as less progression of coronary atherosclerosis compared to moderate treatment. Patients who received intensive therapy showed significant positive changes in plaque buildup volume.
Schering-Plough scientists identified NPC1L1 as a critical protein in the intestinal cholesterol absorption pathway. The discovery provides new insights into how the body regulates cholesterol levels and suggests that Zetia, a cholesterol absorption inhibitor, works by interacting with NPC1L1.
Patients with a history of high cholesterol had a lower risk of cognitive impairment three to six months after stroke. The study found that statin treatment, rather than the cholesterol itself, may be responsible for this effect.
A study found that patients taking statins before leg bypass surgery had better graft patency and lower risk of amputation. Patients on ACE inhibitors also had a lower risk of dying after surgery. The medications' effects outweighed PAD severity and other medical issues.
Researchers analyzed combined data from large prospective studies and found a trend towards fewer hip fractures and nonspine fractures among statin users. However, analysis of clinical trials did not support a protective effect with statin use for hip or nonspine fracture.
A study by Harvard Medical School found that employees treated for chronic illnesses stop taking necessary medications when benefit changes occur, particularly with substantial co-payment increases. Employers who implemented larger co-payment hikes saw higher rates of medication non-adherence and changes in medication regimens.
A new UCLA test measures HDL cholesterol's ability to reduce inflammation, potentially better predicting heart disease risk. The study found that patients with pro-inflammatory HDL had a higher risk of heart disease despite normal or high cholesterol levels.
AstraZeneca's rosuvastatin has an inferior evidence base supporting its safe use compared to competitors. The company is facing unusually acute commercial pressure to force the drug into the market.
A UK multi-centre randomised trial found that statins reduce the risk of heart attacks, strokes or revascularisation operations by about a third in diabetic patients, irrespective of their cholesterol levels. This could prevent at least 10,000 heart attacks, strokes and revascularisation operations each year worldwide.